Form 4: Marimed Inc. President and CEO Jon Levine Reports Stock Transactions

Jon Levine, President and CEO of Marimed Inc., reports the vesting of Restricted Stock Units (RSUs) and subsequent tax withholding, impacting his beneficial ownership of common stock.

Summary

• On April 27, 2025, Jon Levine, President and CEO of Marimed Inc., reported transactions involving common stock and Restricted Stock Units (RSUs).
• 138,889 RSUs vested and converted into shares of common stock on a one-for-one basis.
• The company withheld 48,126 shares of common stock to cover tax obligations related to the RSU vesting at a price of $0.108 per share.
• Following these transactions, Levine directly owns 20,659,529 shares of common stock.
• Levine also indirectly owns 6,684,640 shares through the Jon Levine Family Trust, but disclaims beneficial ownership of these shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions, with no inherent positive or negative sentiment. It's a factual report of insider activity.

Future Outlook

The remaining unvested RSUs will vest on October 27, 2025, according to the agreement between Marimed Inc. and Jon Levine.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, like the CEO, when they have transactions involving the company's securities. It provides transparency to the market regarding insider activity.

Stakeholder Impact

• Shareholders are informed about insider transactions, providing transparency into management's holdings.
• The transactions have a minor impact on the company's outstanding shares due to the vesting of RSUs and tax withholding.

Key Dates

Keywords

Marimed Inc., Jon Levine, MRMD, Form 4, Beneficial Ownership, Restricted Stock Units, RSU, Common Stock, Insider Trading, SEC Filing